The verdict
Our read at a glance.
Whether bimagrumab's muscle-building and fat-reducing effects translate into durable benefit in a specific indication and lead to approval.
- The signal
- Randomized trials show bimagrumab increases muscle mass and reduces fat mass. It did not meet its main goal in inclusion body myositis, but a Phase 2 obesity trial reported fat loss with muscle preservation, including in combination with semaglutide. Its full benefit and safety across indications remain to be established.
- The unknown
- Whether changing body composition this way produces meaningful functional or health benefits, how it performs in larger obesity trials, and its long-term safety.
- Our read
- A real myostatin-pathway antibody that reliably shifts body composition, still investigational and unproven for any approved use. Bimagrumab's muscle and fat effects are real in trials, but a failed muscle-disease study and early obesity data mean it should be read as investigational, not established.
The mechanism
How it works.
Bimagrumab is a monoclonal antibody that binds and blocks the type II activin receptors (ActRII) on muscle cells. Those receptors normally receive myostatin and activin, signals that act as a brake on muscle growth, so blocking the receptor releases that brake and the muscle grows; in trials this is accompanied by a loss of fat mass. The effects on muscle and fat are real in human studies, but the antibody works the same way regardless of disease, and whether that body-composition change translates into clinical benefit is what the trials are still testing.
Safety & regulatory boundary
The consequential part.
Bimagrumab is investigational and not an approved product. It has shown side effects such as muscle spasms and mild diarrhea in trials, and it failed its main muscle-disease endpoint. Results in one indication do not transfer to another, and research-labeled or compounded versions are not an approved product. Its development status does not support use outside trials.
What's next
What we're watching.
Larger obesity trials, combination data with incretin drugs, and any regulatory progress.
Context
Why this is discussed.
Bimagrumab is a prominent example of targeting the myostatin and activin pathway to change body composition, now of particular interest as a way to preserve muscle during weight loss.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2024-10-21
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-11-05
ClinicalTrials.gov · PHASE1 · COMPLETED · 2025-03-25
ClinicalTrials.gov · PHASE2 · WITHDRAWN · 2025-05-23
ClinicalTrials.gov · PHASE2 · COMPLETED · 2022-11-16
ClinicalTrials.gov · PHASE2 · COMPLETED · 2014-12-09
ClinicalTrials.gov · PHASE2 · COMPLETED · 2017-02-01
ClinicalTrials.gov · PHASE2/PHASE3 · COMPLETED · 2014-03-11
Indexed literature (PubMed)12
Melson E et al. · Int J Obes (Lond) · 2025
Kanbay M et al. · Aging Clin Exp Res · 2024
Yanovski SZ et al. · JAMA Intern Med · 2024
Heymsfield SB et al. · JAMA Netw Open · 2021
Petricoul O et al. · Clin Pharmacokinet · 2023
Stefanakis K et al. · Metabolism · 2024
Kaur M et al. · J Basic Clin Physiol Pharmacol · 2024
Kim JW et al. · Arch Pharm Res · 2021
Chavez AM et al. · Curr Opin Clin Nutr Metab Care · 2025
Rooks D et al. · J Cachexia Sarcopenia Muscle · 2020
Rooks D et al. · J Am Geriatr Soc · 2017
Rooks D et al. · JAMA Netw Open · 2020
Keep reading